Department of Pharmaceutical Chemistry, School of Pharmacy, University of Bari, Italy.
AAPS PharmSciTech. 2011 Dec;12(4):1302-11. doi: 10.1208/s12249-011-9695-x. Epub 2011 Sep 27.
Brain tumor treatment employing methotrexate (MTX) is limited by the efflux mechanism of Pg-p on the blood-brain barrier. We aimed to investigate MTX-loaded chitosan or glycol chitosan (GCS) nanoparticles (NPs) in the presence and in the absence of a coating layer of Tween 80 for brain delivery of MTX. The effect of a low Tween 80 concentration was evaluated. MTX NPs were formulated following the ionic gelation technique and size and zeta potential measurements were acquired. Transport across MDCKII-MDR1 monolayer and cytotoxicity studies against C6 glioma cell line were also performed. Cell/particles interaction was visualized by confocal microscopy. The particles were shown to be cytotoxic against C6 cells line and able to overcome MDCKII-MDR1 cell barrier. GCS-based NPs were the most cytotoxic NPs. Confocal observations highlighted the internalization of Tween 80-coated fluorescent NPs more than Tween 80-uncoated NPs. The results suggest that even a low concentration of Tween 80 is sufficient for enhancing the transport of MTX from the NPs across MDCKII-MDR1 cells. The nanocarriers represent a promising strategy for the administration of MTX to brain tumors which merits further investigations under in vivo conditions.
脑肿瘤的治疗采用甲氨蝶呤(MTX),但受到血脑屏障上 Pg-p 外排机制的限制。我们旨在研究载甲氨蝶呤的壳聚糖或乙二醇壳聚糖(GCS)纳米颗粒(NPs),并在存在和不存在吐温 80 涂层的情况下用于 MTX 的脑部递药。评估了低浓度吐温 80 的效果。采用离子凝胶化技术制备 MTX NPs,并进行了粒径和 Zeta 电位测量。还进行了跨 MDCKII-MDR1 单层的转运和针对 C6 神经胶质瘤细胞系的细胞毒性研究。通过共聚焦显微镜观察细胞/颗粒的相互作用。结果表明,这些颗粒对 C6 细胞系具有细胞毒性,并能够克服 MDCKII-MDR1 细胞屏障。基于 GCS 的 NPs 是最具细胞毒性的 NPs。共聚焦观察突出了吐温 80 涂层荧光 NPs 的内化程度超过了未涂层 NPs。结果表明,即使是低浓度的吐温 80 也足以增强 MTX 从 NPs 到 MDCKII-MDR1 细胞的转运。这些纳米载体为脑肿瘤中 MTX 的给药提供了一种很有前途的策略,值得在体内条件下进一步研究。
Eur J Pharm Biopharm. 2015-6
J Control Release. 2011-11-30
Pharmaceutics. 2020-10-23
Front Neurol. 2020-7-30
Am J Nucl Med Mol Imaging. 2014-8-15
Expert Opin Drug Deliv. 2009-10
Int J Pharm. 2009-6-22
Lancet Neurol. 2009-6
J Control Release. 2009-7-1
Eur J Pharm Biopharm. 2009-3-10
Anal Bioanal Chem. 2009-1